The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

Jiuzhou Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 748 million yuan, a year-on-year increase of 18.51%

According to the Zhitong Finance APP, Jiuzhou Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.16 billion yuan, a year-on-year increase of 4.92%. The net profit attributable to shareholders of the listed company was 748 million yuan, a year-on-year increase of 18.51%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 746 million yuan, a year-on-year increase of 20.67%

CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up

CRO concept stocks fluctuated upward, Jiuzhou Pharma hit the daily limit, APELOA rose over 5%, JOINN, Chemspec, OPM, and Haoyuan Pharma followed suit

Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA

Jiuzhou Pharma's subsidiary, Reibo Suzhou, underwent a cGMP on-site inspection by the U.S. FDA from May 19 to 22, 2025, and passed the inspection. This inspection covered six major systems, including quality systems, materials, and production, indicating that Reibo Suzhou meets FDA requirements, providing assurance for the company's expansion into international markets and positively impacting the global regulatory market. The company has established a cGMP quality management system that meets global standards, enhancing its overall competitiveness

Cinda Securities: Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth points

According to the research report from Xinda Securities, Jiuzhou Pharma's DMO business continues to experience high growth, and the layout of new molecular business is expected to become a new growth point. By the first half of 2025, the company has undertaken 1,214 innovative drug active pharmaceutical ingredient CDMO projects, covering multiple therapeutic areas, with the number of late-stage clinical and commercialization projects continuously increasing, driving performance growth. In addition, the company has established a complete technical platform for new molecular businesses such as peptides, conjugates, and small nucleic acid drugs, with the relevant market size expected to reach USD 11 billion by 2030, with a compound annual growth rate of 28.4%